by Nathan Ford and Haileyesus Getahun
Public Health Action, Vol. 6, Nr. 3, 21 September 2016, pp. 158-159
Tuberculosis (TB) remains the leading cause of severe morbidity and mortality among people living with the human immunodeficiency virus (PLHIV) in southern Africa and elsewhere. There is evidence that antiretroviral therapy (ART) reduces the risk of acquiring TB among PLHIV even at higher CD4 cell counts, and modelling using data from nine sub-Saharan African countries suggests that immediate ART will avert over a third of new TB cases by 2050. Published data are supportive of continued expansion of ART coverage as a way to reduce mortality and incidence of both HIV and TB. Nevertheless, it is important to stress that ART alone is unlikely to be sufficient to curb the epidemic of HIV-associated TB.